Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1715)	12/5/2006 4:42:56 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

HEB Also continued its upmove for a second day on a roll, closing at its intraday H. bigcharts.marketwatch.com It seems there could have been some short covering as the volume was higher than yesterday (906,200 vs. 675,100) (The short position increased almost 20% in the last month and was at more than 7x its average daily volume.) Boenning & Scattergood started covering yesterday at "Outperform".<g> The stock that trades around 7.2xBV closed above its Oct.20 H of 2.25 & is now starting to get off from the downtrend coming from its March H at 4.23 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1715)	2/26/2008 4:25:29 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ISPH has been up 18.53% & is still up 10.44% on volume of 388,020 which is > its ADV. bigcharts.marketwatch.com It announced today the results for the 4thQ that showed a loss of $0.51 vs. $0.37 in 2006. The revenue was better $13.9M vs. $8.4M ISPH has reported double digit improvements on revenues for 4 consecutive Qs For 2008 it is also expected that it will be able to trim its loss some to around $1.05/shr vs. $1.61 in 2007 It closed the Yr with $139.7M in cash & equivalents,after $36.34 M in net borrowings & proceeds from the sale of Series A Preferred for $73.6M On Feb 13 it announced that it started its second PIII of TIGER-2, with denufosol tetrasodium inhalation solution for the treatment of CF in which it plans to enroll 350 patients. The "analysts" have a target of $11.33 but if it just can get back to the $8 level it had in January it would be a good % gain.<g> bigcharts.marketwatch.com Bernard